Moreover, Figure 5 showed that HLJDD treatment of AD may be mainly related to calcium, VEGF, and NF-κB signaling pathway, lipid and atherosclerosis, chemical carcinogenesis-receptor activation, dopaminergic synapse, platinum drug resistance, etc. Here, NFKB1 is linked to Alzheimer disease.